Publication:
Data-driven FDG-PET subtypes of Alzheimer's disease-related neurodegeneration.

dc.contributor.authorLevin, Fedor
dc.contributor.authorFerreira, Daniel
dc.contributor.authorLange, Catharina
dc.contributor.authorDyrba, Martin
dc.contributor.authorWestman, Eric
dc.contributor.authorBuchert, Ralph
dc.contributor.authorTeipel, Stefan J
dc.contributor.authorGrothe, Michel J
dc.contributor.authorAlzheimer’s Disease Neuroimaging Initiative
dc.date.accessioned2023-02-09T10:42:41Z
dc.date.available2023-02-09T10:42:41Z
dc.date.issued2021-02-19
dc.description.abstractPrevious research has described distinct subtypes of Alzheimer's disease (AD) based on the differences in regional patterns of brain atrophy on MRI. We conducted a data-driven exploration of distinct AD neurodegeneration subtypes using FDG-PET as a sensitive molecular imaging marker of neurodegenerative processes. Hierarchical clustering of voxel-wise FDG-PET data from 177 amyloid-positive patients with AD dementia enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI) was used to identify distinct hypometabolic subtypes of AD, which were then further characterized with respect to clinical and biomarker characteristics. We then classified FDG-PET scans of 217 amyloid-positive patients with mild cognitive impairment ("prodromal AD") according to the identified subtypes and studied their domain-specific cognitive trajectories and progression to dementia over a follow-up interval of up to 72 months. Three main hypometabolic subtypes were identified: (i) "typical" (48.6%), showing a classic posterior temporo-parietal hypometabolic pattern; (ii) "limbic-predominant" (44.6%), characterized by old age and a memory-predominant cognitive profile; and (iii) a relatively rare "cortical-predominant" subtype (6.8%) characterized by younger age and more severe executive dysfunction. Subtypes classified in the prodromal AD sample demonstrated similar subtype characteristics as in the AD dementia sample and further showed differential courses of cognitive decline. These findings complement recent research efforts on MRI-based identification of distinct AD atrophy subtypes and may provide a potentially more sensitive molecular imaging tool for early detection and characterization of AD-related neurodegeneration variants at prodromal disease stages.
dc.identifier.doi10.1186/s13195-021-00785-9
dc.identifier.essn1758-9193
dc.identifier.pmcPMC7896407
dc.identifier.pmid33608059
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896407/pdf
dc.identifier.unpaywallURLhttps://doi.org/10.1186/s13195-021-00785-9
dc.identifier.urihttp://hdl.handle.net/10668/17199
dc.issue.number1
dc.journal.titleAlzheimer's research & therapy
dc.journal.titleabbreviationAlzheimers Res Ther
dc.language.isoen
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number49
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, N.I.H., Extramural
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.pubmedtypeResearch Support, U.S. Gov't, Non-P.H.S.
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAlzheimer’s disease
dc.subjectFDG-PET
dc.subjectHypometabolism
dc.subjectMild cognitive impairment
dc.subjectProdromal
dc.subjectSubtypes
dc.subject.meshAlzheimer Disease
dc.subject.meshBrain
dc.subject.meshCognitive Dysfunction
dc.subject.meshFluorodeoxyglucose F18
dc.subject.meshHumans
dc.subject.meshMagnetic Resonance Imaging
dc.subject.meshPositron-Emission Tomography
dc.titleData-driven FDG-PET subtypes of Alzheimer's disease-related neurodegeneration.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number13
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC7896407.pdf
Size:
1.62 MB
Format:
Adobe Portable Document Format